Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: Focus on insulin glulisine

References

• [AACE] American Association of Clinical Endocrinologists, American College of EndocrinologyMedical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management—2002 updateEndocr Pract20028Suppl 1408211939758
   PubMedGoogle Scholar
• [ADA] American Diabetes AssociationStandards of medical care in diabetes -2006Diabetes Care200629Suppl 1S4S4216373931
   PubMedGoogle Scholar
• American Diabetes AssociationNational Diabetes Fact Sheet [online]2005 Accessed September 28, 2006. URL: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf
   Google Scholar
• AndersonJBrunelleRLKoivistaVAReduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatmentDiabetes199746265709000704
   PubMed Web of Science ®Google Scholar
• BeckerRHFrickADBurgerFA comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp techniqueExp Clin Endocrinol Diabetes2005113292715926116
   PubMed Web of Science ®Google Scholar
• BeckerRHAFrickADKapizitaCKPharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes [abstract no. 503-P]Diabetes200453Suppl 2A119
   Google Scholar
• BeckerRHAFrickAWesselsDPharmacodynamics and pharmacokinetics of a new rapidly-acting insulin analog, insulin glulisine [abstract no. 471-P]Diabetes200352Suppl 1A110
   Google Scholar
• BertiLKellererMBossenmaierBThe long-acting human insulin analog HOE901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulinHorm Metab Res199830123299566852
   PubMed Web of Science ®Google Scholar
• BrunelleRLLlewelynJAndersonJMeta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetesDiabetes Care1998211726319773738
   PubMed Web of Science ®Google Scholar
• DaileyGRosenstockJMosesRGInsulin glulisine provides improved glycemic control in patients with type 2 diabetesDiabetes Care2004272363815451901
   PubMed Web of Science ®Google Scholar
• DanneTBeckerRHHeiseTPharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetesDiabetes Care2005282100516123473
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med1993329977868366922
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research GroupReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• DreyerMPragerRRobinsonAEfficacy and safety of insulin glulisine in patients with type 1 diabetesHorm Metab Res200537702716308840
   PubMed Web of Science ®Google Scholar
• FrickABeckerRHAWesselsDPharmacokinetic and glucodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites [abstract no. 471-P]Diabetes200352Suppl 1A110
   Google Scholar
• FrickABurgerFScholtzHTime-action profile of insulin glulisine versus regular human insulin and insulin lispro in obese subjects [abstract no. 526-P]Diabetes200452Suppl 2A124
   Google Scholar
• GabryKEApplication number: 21–629 (insulin glulisine)Medical Review [online]2006 Accessed September 9, 2006. URL: http://www.fda.gov/cder/foi/nda/2004/21–629_Apidra_Medr_P1.pdf
   Google Scholar
• GargSAndersonJPerrySLong-term efficacy of humalog in subjects with type 1 diabetes mellitusDiabet Med1999163848710342337
   PubMedGoogle Scholar
• GargSKEllisSLUlrichHInsulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetesExpert Opin Pharmacother200566435115934890
   PubMed Web of Science ®Google Scholar
• GargSSafety, accuracy, and improvement in glucose profiles observed using a 7-day continuous glucose sensorDiabetes Care2006292644917130198
   PubMed Web of Science ®Google Scholar
• GargSRosenstockJWaysKOptimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargineEndocr Pract20051111716033730
   PubMedGoogle Scholar
• GargSUlrichHAchieving goal glycosylated hemoglobin levels in type 2 diabetes mellitus: practical strategies for success with insulin therapyInsulin2006110921
   Google Scholar
• HirschIBEffect of insulin therapy on nonglycemic variables during acute illnessEndocr Pract200410Suppl 2637015251643
   PubMedGoogle Scholar
• HomePDLindholmAHyllebergBImproved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patientsDiabetes Care1998211904099802741
   PubMed Web of Science ®Google Scholar
• HoogmaRPSchumickiDSafety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetesHorm Metab Res2006384293316823727
   PubMed Web of Science ®Google Scholar
• HoweyDCBowsherRRBrunelleRL[Lys(B28),Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulinDiabetes1994433964028314011
   PubMed Web of Science ®Google Scholar
• [IDF] International Diabetes FederationA desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999Diabet Med1999167163010510947
   PubMedGoogle Scholar
• [IDF] International Diabetes FederationExecutive Summary of the Diabetes Atlas, second addition [online]2006 Accessed September 28, 2006. URL: http://www.eatlas.idf.org/
   Google Scholar
• JarosMMartinekVPiechatzekRPharmacokinetics of insulin glulisine in non-diabetic renally impaired patients [abstract no. 1330-P]Diabetes200453Suppl 2A32122
   PubMedGoogle Scholar
• MonnierLLapinskiHColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)Diabetes Care200326881512610053
   PubMed Web of Science ®Google Scholar
• NathanDMClearyPABacklundJYThe Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med200535326435316371630
   PubMed Web of Science ®Google Scholar
• NosekLBeckerRHAFrickADPrandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin [abstract no.588-P]Diabetes200453Suppl 2A13940
   Google Scholar
• OvermannHHeinemannLInection-meal interval: recommendations of diabetologists and how patients handle itDiab Res Clin Pract19994313742
   PubMed Web of Science ®Google Scholar
• PlankJSiebenhoferABergholdASystematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitusArch Intern Med200516513374415983281
   PubMed Web of Science ®Google Scholar
• PolonskyKSSturisJBellGNon-insulin dependent diabetes mellitus: a genitically programmed failure of the beta cell to compensate for insulin resistanceN Engl J Med1996334777838592553
   PubMed Web of Science ®Google Scholar
• RaveKNosekLHeinemannLInsulin glulisine: pharmacokinetic and pharmacodynamic properties in comparison with insulin lispro and regular human insulin in Japanese and caucasian volunteers [abstract no. 603-P]Diabetes200453Suppl 2A143
   Google Scholar
• RossettiLGiaccariADeFronzoRAGlucose toxicityDiabetes Care199013610302192847
   PubMed Web of Science ®Google Scholar
• ShichiriMKishikawaHOhkuboYLong term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patientsDiabetes Care200023Suppl 2B21910860187
   PubMed Web of Science ®Google Scholar
• SobelBEFryeRDetreKMRationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)Trial Circulation200310763642
   PubMed Web of Science ®Google Scholar
• SpitzerHHeiseTHeinemannLInsulin glulisine: faster onset of absorption and action than insulin lispro in lean to obese subjects [abstract no. 0148]Diabetologia200649Suppl 1945
   Google Scholar
• StammbergerISeipkeGBartelsTInsulin glulisine--a comprehensive preclinical evaluationInt J Toxicol200625253316510354
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAWon behalf of the UK Prospective Diabetes Study GroupAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ20003214051210938048
   PubMed Web of Science ®Google Scholar
• TurnerRCCullCAFrighiVfor the UK Prospective Diabetes Study (UKPDS) GroupGlycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)JAMA199928120051210359389
   PubMed Web of Science ®Google Scholar
• [UKPDS] UK Prospective Diabetes Study GroupIntensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet1998352837539742976
   PubMed Web of Science ®Google Scholar
• [UKPDS] UK Prospective Diabetes Study GroupUK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type 2 diabetes: a progressive diseaseDiabetes1995441249587589820
   PubMed Web of Science ®Google Scholar
• WittlinSDWoehrleHJGerichJEInsulin pharmacokineticsInsulin Therapy2002New York, NYMarcel Dekker Inc
   Google Scholar
• World Health OrganizationDiabetes action now [online]2006 Accessed September 9, 2006. URL: http://www.who.int/diabetes/actionnow/en/DANbooklet.pdf
   Google Scholar